GVK Bio, Moulder Center in drug discovery alliance

Under the agreement, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas including cardiovascular, central nervous system (CNS) and metabolic disorders.

GVK Biosciences will also be responsible for reagent generation, assay development and establishing the screening cascade leading to lead identification and optimization.

Both the companies will be jointly responsible for designing the molecules which will be optimized and progressed through lead optimization to a pre-clinical candidate.